1. Academic Validation
  2. Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells

Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells

  • PLoS One. 2015 Dec 31;10(12):e0146073. doi: 10.1371/journal.pone.0146073.
So-Young Kim 1 Sang Eun Park 1 Sang-Mi Shim 2 Sojung Park 1 Kyung Kon Kim 1 3 Seong-Yun Jeong 1 3 4 Eun Kyung Choi 5 4 Jung Jin Hwang 1 3 4 Dong-Hoon Jin 3 4 Christopher Doosoon Chung 1 Inki Kim 1 3
Affiliations

Affiliations

  • 1 ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
  • 2 Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea.
  • 3 Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • 4 Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, Republic of Korea.
  • 5 Department of Radiation Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract

Breast Cancer cells generally develop resistance to TNF-Related Apoptosis-Inducing Ligand (TRAIL) and, therefore, assistance from sensitizers is required. In our study, we have demonstrated that Spleen tyrosine kinase (Syk) inhibitor Bay 61-3606 was identified as a TRAIL sensitizer. Amplification of TRAIL-induced Apoptosis by Bay 61-3606 was accompanied by the strong activation of Bak, caspases, and DNA fragmentation. In mechanism of action, Bay 61-3606 sensitized cells to TRAIL via two mechanisms regulating myeloid cell leukemia sequence-1 (Mcl-1). First, Bay 61-3606 triggered ubiquitin-dependent degradation of Mcl-1 by regulating Mcl-1 phosphorylation. Second, Bay 61-3606 downregulates Mcl-1 expression at the transcription level. In this context, Bay 61-3606 acted as an inhibitor of Cyclin-Dependent Kinase (CDK) 9 rather than Syk. In summary, Bay 61-3606 downregulates Mcl-1 expression in breast Cancer cells and sensitizes Cancer cells to TRAIL-mediated Apoptosis.

Figures
Products